--- title: "Blog: CMC, GMP and biotech manufacturing insights | QLogixCMC" description: "QLogixCMC on what is moving in pharma and biotech manufacturing: onshoring, CSA, AI under Annex 22, comparability, investigations. Interactive figures in every post." url: https://qlogixcmc.com/blog markdown: https://qlogixcmc.com/blog.md publisher: "QLogixCMC (QLogixCMC LLC)" language: en-US --- # What is moving in pharma and biotech manufacturing, and what to do about it Short, practical pieces from QLogixCMC on CMC, quality and compliance: the regulation as published, the way it is inspected, and an interactive figure in each post you can set to your own numbers. - [Technology transfer20 October 20263 min readOnshoring drug manufacturing: the tech transfer and validation path to a US siteOnshoring moves a product's manufacturing to a site that has not made it before. The path is the same every time: a gap analysis between the sending and receiving sites, qualification of the facility and the equipment, transfer of the analytical methods, engineering batches, process performance qualification and a pre-approval inspection. The order in which those run decides whether the site is ready in a year or in two.Read the post](https://qlogixcmc.com/blog/onshoring-drug-manufacturing-tech-transfer) - [AI and digital quality13 October 20263 min readAI in the GMP quality system: what Annex 22 and your next inspector will askEU GMP Annex 22, published for consultation in 2025, is the first GMP text written for artificial intelligence. It allows AI in GMP work on conditions: a defined intended use, test data and acceptance criteria that show the model performs for that use, a person who reviews the output where the application is critical, and the model and its configuration under change control. Inspectors already ask the same questions of any site that has switched on an AI feature in its quality system.Read the post](https://qlogixcmc.com/blog/ai-in-gmp-quality-system-annex-22) - [Sterile manufacturing6 October 20263 min readAnnex 1 three years on: the contamination control strategy inspectors now read firstA contamination control strategy (CCS) is the document, required by the revised EU GMP Annex 1 since August 2023, that sets out how a sterile manufacturing site keeps microbial, pyrogen and particulate contamination out of its products: every control, from facility design and gowning to sterilization, aseptic process simulation and environmental monitoring, with the reasoning that connects them and the data that shows they work. Three years on, inspectors ask for it first, and the gap they find most is not a missing control but a missing connection between the controls and the data.Read the post](https://qlogixcmc.com/blog/annex-1-contamination-control-strategy) - [Validation29 September 20263 min readComputer software assurance: how much testing does your system actually need?Computer software assurance (CSA) is FDA's risk-based approach to establishing confidence that software used in production and in the quality system does what it is intended to do. Its point is that testing effort follows the risk of each function: scripted, documented testing where a failure could affect product quality or patient safety, and unscripted or ad hoc testing, with the result recorded, everywhere else. Most validation packages still test every function the same way.Read the post](https://qlogixcmc.com/blog/computer-software-assurance-how-much-testing) - [CMC and regulatory8 September 20263 min readComparability for cell, gene and mRNA therapies: proving a process change left the product unchangedComparability is the evidence that a product made after a manufacturing change is still the product the clinical data describes. For cell, gene and mRNA therapies the change is almost certain: processes move from academic to commercial scale, from open to closed, from one site or vector supplier to another, often during the pivotal trial. The statistics are unforgiving. With three lots on each side, a real shift and ordinary lot-to-lot variability look alike, and the study fails for lack of data rather than lack of comparability.Read the post](https://qlogixcmc.com/blog/cell-gene-mrna-therapy-comparability) - [Investigations and CAPA18 August 20263 min readWhy 21 CFR 211.192 stays the most-cited observation, and how a backlog really comes down21 CFR 211.192 requires every unexplained discrepancy and every failure of a batch to meet its specifications to be thoroughly investigated, extended to other batches that may have been affected, and recorded with conclusions and follow-up. It has topped FDA's list of drug GMP observations for years because the failure is systemic rather than technical: too many open records, investigations that stop at human error, and CAPAs that are never checked. A backlog is arithmetic before it is anything else.Read the post](https://qlogixcmc.com/blog/211-192-investigations-backlog) ## Talk it through with someone who has run a plant Bring your backlog, your submission timeline or the Form 483. We will tell you plainly what we would do first, what it would take, and what we would leave alone. [Request a meeting](https://qlogixcmc.com/contact)[Email us](mailto:contact@qlogixcmc.com) In the first meeting we cover - What is on your mind: a backlog, a submission, a validation program, an inspection date or a system that is not working - What we would assess first, and what we would leave alone - Whether an engineer on your site, a fixed-scope assessment or a defined deliverable is the right way to start ## More from QLogixCMC - [QLogixCMC home](https://qlogixcmc.com/index.md): CMC consulting for biotech, pharma and CDMOs: Module 3 from IND to BLA, control strategy, GMP quality systems, validation, CAPA and FDA inspection readiness. - [Services](https://qlogixcmc.com/services.md): QLogixCMC services, on site or remote: CMC and regulatory, quality systems, validation and CSA, investigations and CAPA, inspection readiness, GxP systems and AI. - [Request a meeting](https://qlogixcmc.com/contact.md): Talk to QLogixCMC about a CMC submission, your quality system, validation, an investigation backlog or an FDA inspection. We reply to set up a time. - [llms.txt: a summary of the site for AI assistants](https://qlogixcmc.com/llms.txt) - [Site map](https://qlogixcmc.com/sitemap.md) --- Source: https://qlogixcmc.com/blog Cite this page as https://qlogixcmc.com/blog QLogixCMC · contact@qlogixcmc.com · +17146639012